本文選題：膀胱癌 + MicroRNA-200c　； 參考：《天津醫(yī)科大學(xué)》2014年碩士論文

【摘要】：目的： 觀察microRNA-200c及轉(zhuǎn)錄因子ZEB1. ZEB2(SIP1)在膀胱癌組織中的表達(dá)情況,并分析其與腫瘤數(shù)目、腫瘤大小、病理分級(jí)、臨床分期等臨床病理學(xué)參數(shù)之間的關(guān)系。探討microRNA-200c與ZEB1和ZEB2在膀胱癌組織中表達(dá)的相關(guān)性,從而為進(jìn)一步研究microRNA-200c在膀胱癌EMT過(guò)程中的作用及其可能的作用機(jī)制提供依據(jù),并闡明其在膀胱癌患者中的臨床預(yù)后意義。 方法： 對(duì)58例膀胱癌組織(實(shí)驗(yàn)組)及58例正常膀胱粘膜組織(對(duì)照組)采用實(shí)時(shí)定量PCR方法檢測(cè)microRNA-200c的相對(duì)表達(dá)量,采用免疫組織化學(xué)方法(超敏型S-P法)檢測(cè)ZEB1、ZEB2的表達(dá)情況,分別比較三者在實(shí)驗(yàn)組和對(duì)照組中的表達(dá)差異,并分析三者在膀胱癌組織中的表達(dá)與腫瘤數(shù)目、腫瘤大小、病理分級(jí)、臨床分期等臨床病理學(xué)參數(shù)之間的關(guān)系,進(jìn)一步分析其表達(dá)之間的關(guān)聯(lián)性。 結(jié)果： 1. MicroRNA-200c及ZEB1、ZEB2在膀胱癌中的表達(dá)均高于其在正常膀胱粘膜中的表達(dá)(P0.05)。 2.膀胱癌中microRNA-200c的表達(dá)差異與腫瘤數(shù)目及腫瘤大小無(wú)關(guān)(P0.05),而與腫瘤病理分級(jí)及臨床分期有關(guān),microRNA-200c的表達(dá)強(qiáng)度在非肌層浸潤(rùn)性膀胱癌組高于肌層浸潤(rùn)性膀胱癌組(P0.05),在低分級(jí)膀胱癌組高于高分級(jí)膀胱癌組(P0.05)。 3.膀胱癌中ZEB1及ZEB2的表達(dá)差異與腫瘤數(shù)目及腫瘤大小無(wú)關(guān)(P0.05),而與腫瘤病理分級(jí)及臨床分期有關(guān),ZEB1及ZEB2在肌層浸潤(rùn)性膀胱癌中的表達(dá)陽(yáng)性率高于其在非肌層浸潤(rùn)性膀胱癌中的表達(dá)陽(yáng)性率(P0.05),在高分級(jí)膀胱癌中的表達(dá)陽(yáng)性率高于其在低分級(jí)膀胱癌中的表達(dá)陽(yáng)性率(P0.05)。 4.在膀胱癌組織中,microRNA-200c的表達(dá)水平與ZEB1的表達(dá)之間有明顯相關(guān)性,但和ZEB2的表達(dá)之間無(wú)明顯相關(guān)性,microRNA-200c的表達(dá)量在ZEB1陰性組明顯高于ZEB1陽(yáng)性組(P0.05),但在ZEB2陰性組和ZEB2陽(yáng)性組之間無(wú)明顯差異(P0.05)。 結(jié)論： 1. MicroRNA-200c在膀胱癌中的表達(dá)強(qiáng)度隨腫瘤病理分級(jí)和臨床分期的增加而降低,ZEB1和ZEB2在膀胱癌中的表達(dá)水平隨腫瘤病理分級(jí)和臨床分期的增加而增高,提示它們可能參與了膀胱癌的發(fā)生、發(fā)展過(guò)程,并在其侵襲和轉(zhuǎn)移過(guò)程中發(fā)揮作用。通過(guò)檢測(cè)膀胱癌中microRNA-200c及ZEB1、ZEB2的表達(dá)有助于膀胱癌的診斷和治療,并可能成為判斷膀胱癌預(yù)后的重要指標(biāo)。 2. MicroRNA-200c在膀胱癌中的表達(dá)與ZEB1的表達(dá)之間存在明顯相關(guān)性,在microRNA-200c表達(dá)上調(diào)時(shí),會(huì)出現(xiàn)ZEB1的低表達(dá),提示ZEB1的表達(dá)可能受到microRNA-200c的調(diào)節(jié),ZEB1可能是microRNA-200c的靶基因,它們共同參與了膀胱癌的EMT過(guò)程。 3.本研究為抑制膀胱癌的侵襲和轉(zhuǎn)移提供了新的研究方向,ZEB1、ZEB2有望成為治療膀胱癌新的干預(yù)靶點(diǎn),microRNA-200c可能成為膀胱癌新的腫瘤標(biāo)記物。
[Abstract]:Objective: MicroRNA-200c and transcription factor ZEB1 were observed. The expression of ZEB2 and SIP1 in bladder cancer and its relationship with tumor number, tumor size, pathological grade, clinical stage and other clinicopathological parameters were analyzed. To investigate the correlation between microRNA-200c, ZEB1 and ZEB2 expression in bladder cancer tissues, so as to provide a basis for further study on the role of microRNA-200c in the process of bladder cancer EMT and its possible mechanism, and to elucidate the clinical prognostic significance of microRNA-200c in bladder cancer patients. Methods: The relative expression of microRNA-200c in 58 cases of bladder cancer (experimental group) and 58 cases of normal bladder mucosa (control group) was detected by real-time quantitative PCR, and the expression of ZEB1 and ZEB2 was detected by immunohistochemistry (hypersensitive S-P method). To compare the difference of expression between the three groups in the experimental group and the control group, and to analyze the relationship between the expression of the three proteins and the clinicopathological parameters, such as tumor number, tumor size, pathological grade, clinical stage, and so on. Further analysis of the relationship between its expression. Results: 1. The expression of MicroRNA-200c and ZEB2 in bladder cancer was higher than that in normal bladder mucosa. 2. The difference of microRNA-200c expression in bladder cancer was not related to the number and size of tumor, but the expression of microRNA-200c was related to the pathological grade and clinical stage of the tumor. The expression of microRNA-200c in non-muscular invasive bladder cancer group was higher than that in myometrial invasive bladder cancer group, and in the low score, the expression level of microRNA-200c was higher in non-myometrial invasive bladder cancer group than in myometrial invasive bladder cancer group. The grade grade bladder cancer group was higher than the high grade bladder cancer group (P 0.05). 3. The difference of ZEB1 and ZEB2 expression in bladder cancer is not related to the number and size of tumor, but the positive rate of ZEB1 and ZEB2 in myometrial invasive bladder cancer is higher than that in non-myometrial invasive bladder cancer. The positive rate of cysteine carcinoma was higher in high grade bladder cancer than in low grade bladder cancer. 4. There was a significant correlation between the expression of microRNA-200c and the expression of ZEB1 in bladder cancer. The expression of microRNA-200c in ZEB1 negative group was significantly higher than that in ZEB1 positive group, but there was no significant difference between ZEB2 negative group and ZEB2 positive group. Conclusion: 1. The expression of MicroRNA-200c in bladder cancer decreased with the increase of tumor pathological grade and clinical stage, and the expression of ZEB1 and ZEB2 in bladder cancer increased with the increase of tumor pathological grade and clinical stage, suggesting that they may be involved in the occurrence of bladder cancer. Development process and play a role in its invasion and metastasis. The expression of microRNA-200c and ZEB1 / ZEB2 in bladder cancer is helpful to the diagnosis and treatment of bladder cancer and may be an important index to judge the prognosis of bladder cancer. 2. There was a significant correlation between the expression of MicroRNA-200c and the expression of ZEB1 in bladder cancer. When the expression of microRNA-200c was up-regulated, the low expression of ZEB1 appeared, suggesting that the expression of ZEB1 might be regulated by microRNA-200c. ZEB1 might be the target gene of microRNA-200c. They are involved in the EMT process of bladder cancer. 3. This study provides a new research direction for inhibiting invasion and metastasis of bladder cancer. ZEB1 / ZEB2 may be a new intervention target for bladder cancer. MicroRNA-200c may be a new tumor marker for bladder cancer.
【學(xué)位授予單位】：天津醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R737.14

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 石夏榮,俞吉安;MicroRNA特征與功能[J];上海交通大學(xué)學(xué)報(bào);2004年05期

，

本文編號(hào)：1842983